SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

CIPLA

BSE: 500087 07 Sep 2025
Healthcare
₹ 1577.65
Cipla Ltd., specializes in Pharmaceuticals within the Healthcare sector.

CIPLA - Share Price & Details

Market Cap
₹1,25,477
High /Low
1,702 / 1,310
Stock P/E
23.3
Book Value
₹386.0
Dividend Yield
0.84
ROCE
22.7
ROE
₹17.8
Face Value
2.0
PEG Ratio
0.9
EVEBITDA
₹15.4
Debt
438
CMP / FCF
44.8
Debt to equity
₹0.01
NP Ann
5,269
High price all time
1,702
Piotroski score
₹7.0
Graham Number
762.0
No. Eq. Shares
80.8
Net CF
₹30.3
Net profit
5,385
Price to book value
4.02
Interest Coverage
₹121.0
Low price all time
84.7
Industry PE
33.1
Reserves
₹31,032
Free Cash Flow
₹3,490

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.4691.0
Triochem Products Ltd.,NANANANA0
CIPLA LTD.53172.413031.350461.716.121,25,47723.3
TORRENT PHARMACEUTICALS LTD.26110.05510.026160.016.2812112860.0
Max Healthcare Institute Limit7738.71660.36940.21.711375194.8

Peer Comparison Chart


About CIPLA

Cipla Ltd.,, with Security Code 500087, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

(06 Sep 2025)
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to...
Read more →

Cipla introduces HUENA® – First non-antibiotic drug for recurring UT infections

(06 Sep 2025)
Mumbai, 6 Sept 2025: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the launch of Methenamine Hippurate,...
Read more →

Cipla Launches Non-Antibiotic UTI Treatment HUENA

(05 Sep 2025)
Cipla introduces HUENA, a non-antibiotic treatment for recurrent urinary tract infections (UTIs) in India. Reduces antibiotic reliance and...
Read more →

Cipla launches HUENA, India’s first non-antibiotic drug to treat UTIs

(05 Sep 2025)
Cipla has announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract...
Read more →

Cipla rolls out nation’s first non-antibiotic medication for recurrent UTI cases

(05 Sep 2025)
New Delhi, Sep 5: Cipla on Friday announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from...
Read more →

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

(04 Sep 2025)
The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from $1.32 billion in 2024 to $2.53 billion by 2033,...
Read more →

Company Updates